Systematic review / meta-analysis / 2015
A review of 26 clinical studies found evidence for pomegranate preparations in cardiovascular diseases was of poor quality.
A systematic review critically evaluated clinical evidence from 26 clinical studies on dietary pomegranate preparations in the prevention and treatment of cardiovascular diseases. Overall study quality was poor, and even in the best studies, indications of benefit did not reach conventional levels of statistical significance. The only study with a definitive design evaluated a biochemical endpoint (blood concentrations of myeloperoxidase after a single dose) rather than a clinical endpoint, and only 10 of the 26 studies reported HPLC data on co-active ingredients.
- Study type
- Systematic review of clinical studies
- Who was studied
- 26 clinical studies of pomegranate preparations
- What was measured
- Prevention and treatment of cardiovascular diseases and biochemical markers
THE PAPER
A critical evaluation of the clinical evidence for pomegranate preparations in the prevention and treatment of cardiovascular diseases.
Vlachojannis C, Erne P, Schoenenberger AW, Chrubasik-Hausmann S. Phytother Res, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.